JFG
BMRN icon

Jefferies Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,600
Closed -$495K – 1710
2023
Q3 		$495K Buy
5,600
+600
+12% +$53.4K ﹤0.01% 1063
2023
Q2 		$433K Sell
5,000
-5,000
-50% -$471K ﹤0.01% 1225
2023
Q1 		$972K Buy
+10,000
New +$1.04M 0.01% 905

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's BMRN Position: Q1 2026 in Review

Jefferies Financial Group increased its BioMarin Pharmaceuticals (BMRN) stake by 0.24% in Q1 2026, buying an estimated $65.8K and bringing the position to 468,146 shares worth $26.4M. The position accounts for 0.18% of the portfolio, ranked #89.

Jefferies Financial Group first reported a position in BMRN in Q4 2022 and has held it in 10 quarters since. The position peaked at $27.8M in Q4 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Jefferies Financial Group held 468,146 shares of BioMarin Pharmaceuticals worth $26.4M as of Q1 2026.
  • Jefferies Financial Group bought 1,128 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $65.8K.
  • BioMarin Pharmaceuticals made up 0.18% of Jefferies Financial Group's portfolio in Q1 2026, its #89 holding.
  • Jefferies Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • Jefferies Financial Group's BioMarin Pharmaceuticals position peaked at $27.8M in Q4 2025.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.